Cargando…

Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects

Prion diseases are rare and fatal neurodegenerative disorders that can be sporadic, inherited or acquired by infection. Based on a national surveillance program in the Netherlands we describe here the clinical, neuropathological, genetic and molecular characteristics of 162 patients with neuropathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Casper, Parchi, Piero, Capellari, Sabina, Ibrahim-Verbaas, Carla A., Schuur, Maaike, Strammiello, Rosaria, Corrado, Patrizia, Bishop, Matthew T., van Gool, Willem A., Verbeek, Marcel M., Baas, Frank, van Saane, Wesley, Spliet, Wim G. M., Jansen, Gerard H., van Duijn, Cornelia M., Rozemuller, Annemieke J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340342/
https://www.ncbi.nlm.nih.gov/pubmed/22558438
http://dx.doi.org/10.1371/journal.pone.0036333
_version_ 1782231451619557376
author Jansen, Casper
Parchi, Piero
Capellari, Sabina
Ibrahim-Verbaas, Carla A.
Schuur, Maaike
Strammiello, Rosaria
Corrado, Patrizia
Bishop, Matthew T.
van Gool, Willem A.
Verbeek, Marcel M.
Baas, Frank
van Saane, Wesley
Spliet, Wim G. M.
Jansen, Gerard H.
van Duijn, Cornelia M.
Rozemuller, Annemieke J. M.
author_facet Jansen, Casper
Parchi, Piero
Capellari, Sabina
Ibrahim-Verbaas, Carla A.
Schuur, Maaike
Strammiello, Rosaria
Corrado, Patrizia
Bishop, Matthew T.
van Gool, Willem A.
Verbeek, Marcel M.
Baas, Frank
van Saane, Wesley
Spliet, Wim G. M.
Jansen, Gerard H.
van Duijn, Cornelia M.
Rozemuller, Annemieke J. M.
author_sort Jansen, Casper
collection PubMed
description Prion diseases are rare and fatal neurodegenerative disorders that can be sporadic, inherited or acquired by infection. Based on a national surveillance program in the Netherlands we describe here the clinical, neuropathological, genetic and molecular characteristics of 162 patients with neuropathologically confirmed prion disease over a 12-year period (1998–2009). Since 1998, there has been a relatively stable mortality of Creutzfeldt-Jakob disease (CJD) in the Netherlands, ranging from 0.63 to 1.53 per million inhabitants per annum. Genetic analysis of the codon 129 methionine/valine (M/V) polymorphism in all patients with sporadic CJD (sCJD) showed a trend for under-representation of VV cases (7.0%), compared with sCJD cohorts in other Western countries, whereas the MV genotype was relatively over-represented (22,4%). Combined PrP(Sc) and histopathological typing identified all sCJD subtypes known to date, except for the VV1 subtype. In particular, a “pure" phenotype was demonstrated in 60.1% of patients, whereas a mixed phenotype was detected in 39.9% of all sCJD cases. The relative excess of MV cases was largely accounted for by a relatively high incidence of the MV 2K subtype. Genetic analysis of the prion protein gene (PRNP) was performed in 161 patients and showed a mutation in 9 of them (5.6%), including one FFI and four GSS cases. Iatrogenic CJD was a rare phenomenon (3.1%), mainly associated with dura mater grafts. Three patients were diagnosed with new variant CJD (1.9%) and one with variably protease-sensitive prionopathy (VPSPr). Post-mortem examination revealed an alternative diagnosis in 156 patients, most commonly Alzheimer's disease (21.2%) or vascular causes of dementia (19.9%). The mortality rates of sCJD in the Netherlands are similar to those in other European countries, whereas iatrogenic and genetic cases are relatively rare. The unusual incidence of the VV2 sCJD subtype compared to that reported to date in other Western countries deserves further investigation.
format Online
Article
Text
id pubmed-3340342
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33403422012-05-03 Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects Jansen, Casper Parchi, Piero Capellari, Sabina Ibrahim-Verbaas, Carla A. Schuur, Maaike Strammiello, Rosaria Corrado, Patrizia Bishop, Matthew T. van Gool, Willem A. Verbeek, Marcel M. Baas, Frank van Saane, Wesley Spliet, Wim G. M. Jansen, Gerard H. van Duijn, Cornelia M. Rozemuller, Annemieke J. M. PLoS One Research Article Prion diseases are rare and fatal neurodegenerative disorders that can be sporadic, inherited or acquired by infection. Based on a national surveillance program in the Netherlands we describe here the clinical, neuropathological, genetic and molecular characteristics of 162 patients with neuropathologically confirmed prion disease over a 12-year period (1998–2009). Since 1998, there has been a relatively stable mortality of Creutzfeldt-Jakob disease (CJD) in the Netherlands, ranging from 0.63 to 1.53 per million inhabitants per annum. Genetic analysis of the codon 129 methionine/valine (M/V) polymorphism in all patients with sporadic CJD (sCJD) showed a trend for under-representation of VV cases (7.0%), compared with sCJD cohorts in other Western countries, whereas the MV genotype was relatively over-represented (22,4%). Combined PrP(Sc) and histopathological typing identified all sCJD subtypes known to date, except for the VV1 subtype. In particular, a “pure" phenotype was demonstrated in 60.1% of patients, whereas a mixed phenotype was detected in 39.9% of all sCJD cases. The relative excess of MV cases was largely accounted for by a relatively high incidence of the MV 2K subtype. Genetic analysis of the prion protein gene (PRNP) was performed in 161 patients and showed a mutation in 9 of them (5.6%), including one FFI and four GSS cases. Iatrogenic CJD was a rare phenomenon (3.1%), mainly associated with dura mater grafts. Three patients were diagnosed with new variant CJD (1.9%) and one with variably protease-sensitive prionopathy (VPSPr). Post-mortem examination revealed an alternative diagnosis in 156 patients, most commonly Alzheimer's disease (21.2%) or vascular causes of dementia (19.9%). The mortality rates of sCJD in the Netherlands are similar to those in other European countries, whereas iatrogenic and genetic cases are relatively rare. The unusual incidence of the VV2 sCJD subtype compared to that reported to date in other Western countries deserves further investigation. Public Library of Science 2012-04-30 /pmc/articles/PMC3340342/ /pubmed/22558438 http://dx.doi.org/10.1371/journal.pone.0036333 Text en Jansen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jansen, Casper
Parchi, Piero
Capellari, Sabina
Ibrahim-Verbaas, Carla A.
Schuur, Maaike
Strammiello, Rosaria
Corrado, Patrizia
Bishop, Matthew T.
van Gool, Willem A.
Verbeek, Marcel M.
Baas, Frank
van Saane, Wesley
Spliet, Wim G. M.
Jansen, Gerard H.
van Duijn, Cornelia M.
Rozemuller, Annemieke J. M.
Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title_full Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title_fullStr Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title_full_unstemmed Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title_short Human Prion Diseases in The Netherlands (1998–2009): Clinical, Genetic and Molecular Aspects
title_sort human prion diseases in the netherlands (1998–2009): clinical, genetic and molecular aspects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340342/
https://www.ncbi.nlm.nih.gov/pubmed/22558438
http://dx.doi.org/10.1371/journal.pone.0036333
work_keys_str_mv AT jansencasper humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT parchipiero humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT capellarisabina humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT ibrahimverbaascarlaa humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT schuurmaaike humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT strammiellorosaria humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT corradopatrizia humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT bishopmatthewt humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT vangoolwillema humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT verbeekmarcelm humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT baasfrank humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT vansaanewesley humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT splietwimgm humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT jansengerardh humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT vanduijncorneliam humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects
AT rozemullerannemiekejm humanpriondiseasesinthenetherlands19982009clinicalgeneticandmolecularaspects